Latest: FDA Approves New Biosimilar for Oncology Treatment
Oncology

Pembrolizumab Combo Improves pCR Rate in Advanced Gastric/GEJ Cancer

by Cancer Network
0 Comments
0 Mins
Data from KEYNOTE-585 showed that adding pembrolizumab to chemotherapy did not negatively impact health-related quality of life vs placebo/chemotherapy.
Tags:
Cancer Network
Author

Cancer Network

Previous Post
MRD Testing Could Cut Costs, Refine Blood Cancer Care: Ravi Vij, MD, MBA
Next Post
CMMI Puts Early EOM Data Online, to Surprise of Participants
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago